Abiopharma

🔍 MPM BIOVENTURES 2018, L.P. (Executive)

Company: Entrada Therapeutics, Inc. (TRDA)

Report Date: 2026-08-24

Detailed Transactions and Holdings:

• Sold 21,623 shares of Common Stock at $7.34 per share (Direct)
  Date: 2026-08-24 | Code: S | equity_swap_involved: 0 | shares_owned_after: 4,359,439.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
• Sold 26,522 shares of Common Stock at $7.54 per share (Direct)
  Date: 2026-08-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 4,332,917.00 | transaction_form_type: 4 | Footnotes: F5, F6, F4
• Sold 14,569 shares of Common Stock at $7.06 per share (Direct)
  Date: 2026-08-26 | Code: S | equity_swap_involved: 0 | shares_owned_after: 4,318,348.00 | transaction_form_type: 4 | Footnotes: F8, F9, F4

Footnotes:

• F1: The shares were sold as follows: 9,819 by MPM BioVentures 2014, L.P. ("BV 2014"), 655 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 338 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 10,077 by MPM BioVentures 2018, L.P. ("BV 2018"), 535 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 199 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC.
• F2: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.0852 to $7.58 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
• F3: The shares are held as follows: 1,979,549 by BV 2014, 132,032 by BV 2014(B), 68,137 by AM BV2014, 2,031,644 by BV 2018, 107,980 by BV 2018(B) and 40,097 by AM BV2018.
• F4: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
• F5: The shares were sold as follows: 12,043 by BV 2014, 803 by BV 2014(B), 415 by AM BV2014, 12,360 by BV 2018, 657 by BV 2018(B) and 244 by AM BV2018.
• F6: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.28 to $7.6421 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
• F7: The shares are held as follows: 1,967,506 by BV 2014, 131,229 by BV 2014(B), 67,722 by AM BV2014, 2,019,284 by BV 2018, 107,323 by BV 2018(B) and 39,853 by AM BV2018.
• F8: The shares were sold as follows: 6,615 by BV 2014, 441 by BV 2014(B), 228 by AM BV2014, 6,790 by BV 2018, 361 by BV 2018(B) and 134 by AM BV2018.
• F9: Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.55 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
• F10: The shares are held as follows: 1,960,891 by BV 2014, 130,788 by BV 2014(B), 67,494 by AM BV2014, 2,012,494 by BV 2018, 106,962 by BV 2018(B) and 39,719 by AM BV2018.
• REMARKS: See Form 4 for MPM BioVentures 2014, L.P for additional members of this joint filing.